The global RNA therapeutics and vaccines market is projected to reach USD 940 million by 2035, growing at a CAGR of 68%. This ...

Moderna (MRNA) stock in focus as the company cancels plans for an mRNA manufacturing plant in Japan amid a challenging ...

A specially engineered antibody that can accurately deliver RNA treatments into hard-to-reach and hard-to-treat tumors ...

Once injected into the bloodstream, the antibody TMAB3, combined with a type of RNA that stimulates an innate immune reaction ...

Guoping Li, Ph.D., of the Department of Anesthesia, Critical Care & Pain Medicine at Massachusetts General Hospital, is the ...

A specially engineered antibody capable of delivering RNA therapies to hard-to-reach, treatment-resistant tumors ...

Moderna Japan had planned to build an mRNA drug plant at Shonan Health Innovation Park in Kanagawa prefecture. The company shelved the plan, citing weak demand for vaccines and a poor business ...

Cells contain helper molecules called transfer RNAs (tRNAs), which carry building blocks (amino acids) to make proteins.

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

The Tissue Nanotransfection Market is gaining significant traction in the field of regenerative medicine due to its ...

PDF for Biology from the official Rajasthan Board website. Access chapter-wise details for Biology with the link to download ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.